Skip to main content
. 2018 Jul 3;9(51):29548–29564. doi: 10.18632/oncotarget.25434

Figure 7. Prognostic role of lncRNA signature in GBM.

Figure 7

(A) Univarate Cox proportional hazard regression analysis of five lncRNAs using TCGA RNA-Seq. data. (B) Univariate and multivariate Cox proportional hazard regression analysis of lncRNA signature risk score with age, G-CIMP methylation status, IDH mutation and MGMT promoter methylation status. (C) lncRNA risk score distribution of the GBM patients from TCGA RNA-Seq cohort. (D) Patient survival status along with risk score from TCGA RNA sequencing cohort. (E) Kaplan–Meier survival estimates overall survival of GBM patients according to the lncRNA expression signature. (F) Heat map of five lncRNAs expression profiles of GBM patients; rows represent lncRNAs, and columns represent patients. The dotted white line represents the lncRNA signature cut-off dividing patients into low-risk and high-risk groups.